Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults at least 18 years of age~* Has advanced (unresectable Stage III) or metastatic (Stage IV) melanoma that is BRAF mutation positive (V600E)~* Is treatment naive for advanced (unresectable) or metastatic melanoma, with the exception of Interleukin 2 (IL-2) which is allowed.~* Has measurable disease according to RECIST 1.1 criteria.~* Women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study treatment.~* Women with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication.~* Men with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication.~* Must have adequate organ function.~* Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.~Exclusion Criteria:~* Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy or surgery).~* Evidence of active central nervous system (CNS) disease.~* Previous treatment for metastatic melanoma, including treatment with BRAF or MEK inhibitor.~* A history of other malignancy. Subjects who have been disease-free for 5 years or subjects with a history of complete resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~* History of Human Immunodeficiency Virus (HIV) infection.~* Certain cardiac abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK2118436 (Type: EXPERIMENTAL): Subjects in this arm will receive GSK2118436 150 mg twice daily.
- Dacarbazine (DTIC) (Type: ACTIVE_COMPARATOR): Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
- Crossover (Type: EXPERIMENTAL): Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).